

"Onabotulinum Toxin A for Cricopharyngeal Dysfunction in Movement Disorders: A double Blinded Randomized Trial"



Sakoon Saggu,¹ Elavarasi A,¹ Soumya Jagannath Mohapatra,² Rajender Behera,³ Roopa Rajan,¹ Manjari Tripathi,¹ Achal Srivastava,¹ Rohit Bhatia,¹ Deepti Vibha,¹ Rajesh Kumar Singh,¹ Divya MR,¹ Animesh Das,¹ Divyani Garg,¹ Jasmine Parihar,¹ Pramod Garg,² Deepak Gunjan,² Mritunjay Kumar⁴

¹Department of Neurology; ²Department of Gastroenterology; ³Department of Radiology, ⁴ Department of Anesthesiology

All India Institute of Medical Sciences, New Delhi

Funding Agency: Indian Council of Medical Research



Introduction


- Swallowing is a highly coordinated neurological process involving sequential and overlapping movements of various craniofacial, pharyngo-esophageal, and laryngeal muscles to facilitate the passage of food and oral secretions from the mouth to the esophagus.
- Any disruption in this coordinated sequence due to neurological disorders can result in swallowing difficulties, categorized as oropharyngeal or pharyngo-esophageal dysphagia.
- The upper esophageal sphincter (UES) plays a vital role in swallowing by temporarily relaxing to allow food passage while being pulled forward and upward by the suprahyoid muscles, ensuring its active opening.
- At rest, the UES remains closed, preventing gastric and esophageal contents from refluxing into the hypopharynx and maintaining airway protection during breathing and between swallowing.
- Impaired relaxation of the cricopharyngeal muscle, known as cricopharyngeal dysfunction (CPD), can lead to swallowing difficulties, weight loss, aspiration pneumonia, airway obstruction, and dependency on alternative feeding methods such as nasogastric tubes or liquid diets.
- CPD significantly affects patients' quality of life and may require medical intervention to prevent serious complications related to malnutrition and aspiration.
- Botulinum toxin injections offer a less invasive treatment than myotomy, but no randomized trials confirm its efficacy and the evidence remains insufficient for definitive clinical recommendations.

Objectives

- The study aims to evaluate the improvement in swallowing function and related parameters, while also monitoring adverse effects such as worsening dysphagia and vocal cord palsy, in patients receiving Botox compared to those receiving a placebo.

Methodology

- Patients were randomly assigned to the intervention (Group 1) or placebo (Group 2) using sealed envelopes.
- Group 1 received onabotulinum toxin (50U in 2 mL saline), while Group 2 received saline.
- After informed consent, patients were evaluated with a symptom questionnaire.
- During endoscopy, botox/placebo were injected in 4 quadrants using a 23G needle. Follow-ups at 3 weeks and 3 months assessed symptoms, swallowing function, repeat endoscopy, and barium swallow outcomes.
- Data were recorded in REDCap for analysis.



Video assessment



“Onabotulinum Toxin A for Cricopharyngeal Dysfunction in Movement Disorders: A double Blinded Randomized Trial”



Sakoon Saggu,¹ Elavarasi A,¹ Soumya Jagannath Mohapatra,² Rajender Behera,³ Roopa Rajan,¹ Manjari Tripathi,¹ Achal Srivastava,¹ Rohit Bhatia,¹ Deepti Vibha,¹ Rajesh Kumar Singh,¹ Divya MR,¹ Animesh Das,¹ Divyani Garg,¹ Jasmine Parihar,¹ Pramod Garg,² Deepak Gunjan,² Mritunjay Kumar⁴

¹Department of Neurology; ²Department of Gastroenterology; ³Department of Radiology, ⁴ Department of Anesthesiology

All India Institute of Medical Sciences, New Delhi
Funding Agency: Indian Council of Medical Research



Results

- At 3-week follow-up:
- 27.3% showed moderate improvement
- 9% showed significant improvement
- 18.2% had minimal improvement
- 45.5% had no meaningful change in swallowing function.
- Improvements were assessed through self-report and biscuit swallowing time.
- No adverse events were reported

Table 1: summarizing the baseline assessment findings

| DiagnosisT | Segmental dystonia | Dystonia ataxia | Segmental dystonia | Generalized dystonia | Cervical Dystonia | Acute onset segmental dystoniA |
|--|--------------------|-----------------|--------------------|----------------------|-------------------|--------------------------------|
| Progression of Dysphagia | no | yes | yes | yes | Yes | Yes |
| Dysarthria | Yes | Yes | Yes | Yes | yes | Yes |
| Laryngeal & Hyoid Elevation (Barium swallow) | Present | Present | Present | Present | Present | Present |
| Pharyngeal Constriction Ratio | 0 | 0 | 0 | 0 | 0 | 0 |
| PES Opening Duration (s) | 0.66 | 0.733 | 1.33 | 0.46 | 0.4 | 0.4 |
| PES Opening Size (mm) | 8.3 | 18 | 11.3 | 8.5 | 4.28 | 4.28 |
| Oro-pharyngeal Transit Time (s) | 0.66 | 0.73 | 0.4 | 0.3 | 0.2 | 0.2 |
| Hypo-pharyngeal Transit Time (s) | 0.73 | 1.46 | 1.53 | 0.6 | 0.134 | 0.4 |
| Pharyngeal Diameter at Cricopharyngeus (mm) | 13 | 19 | 7.1 | 8.5 | 20.95 | 11.44 |
| Pharyngeal squeeze maneuver | Resistance felt | Resistance felt | Resistance felt | Resistance felt | Resistance felt | Resistance felt |
| Pooling of vallecular secretion | Absent | Absent | Absent | Present | Present | Present |

Conclusion

- Botox appears safe and effective for CPD-related dysphagia, especially in dystonia. Further analysis post-unblinding and a larger cohort will strengthen these findings and validate the novel assessment approach.
- Both FEES and barium swallow fluoroscopy are essential for comprehensive dysphagia assessment, and optimizing quantitative parameters will enhance patient outcomes and management.

References

1. Kuhn MA, Belafsky PC. Management of cricopharyngeus muscle dysfunction. Otolaryngol Clin North Am. 2013;46(6):1087-1099. doi:10.1016/j.otc.2013.08.006
2. Kelly EA, Koszewski IJ, Jaradeh SS, Merati AL, Blumin JH, Bock JM. Botulinum toxin injection for the treatment of upper esophageal sphincter dysfunction. Ann Otol Rhinol Laryngol. 2013;122(2):100-108. doi:10.1177/000348941312200205
3. Samal P, Goyal V, Makharia GK, et al. Transfer Dysphagia Due to Focal Dystonia. J Mov Disord. 2018;11(3):129-132. doi:10.14802/jmd.17081
4. Terré R, Vallès M, Panadés A, Mearin F. Long-lasting effect of a single botulinum toxin injection in the treatment of oropharyngeal dysphagia secondary to upper esophageal sphincter dysfunction: A pilot study. Scand J Gastroenterol. 2008;43(11):1296-1303. doi:10.1080/00365520802245403